XML 27 R15.htm IDEA: XBRL DOCUMENT
v3.22.4

Stock Award Plans | 12 Months Ended
--- | ---
Dec. 31, 2022
Stock Award Plans [Abstract] |
Stock Award Plans | (8) Stock Award Plans The Company has share-based compensation plans which are described below. The compensation cost that has been charged against earnings for the Company’s stock award plans and the income tax benefit recognized in the statement of earnings for stock awards were as follows (in thousands):
|  | Year Ended December 31, |
|  | 2022 |  |  | 2021 |  |  | 2020 |
Compensation cost |  | $ | 13,865 |  |  | $ | 15,713 |  |  | $ | 14,722 |
Income tax benefit |  | $ | 3,533 |  |  | $ | 4,410 |  |  | $ | 4,143 |
The Company has an employee stock award plan for selected officers and other key employees which provides for the issuance of RSUs, stock options, restricted stock awards, and performance awards. Restricted stock and RSUs generally vest ratably over five years, however, the plan includes a provision for the continued vesting of unvested stock options and RSUs for employees who meet certain years of service and age requirements at the time of their retirement. The provision results in shorter expense accrual periods on stock options and RSUs granted to employees who are nearing retirement and meet the service and age requirements. At December 31, 2022, there we re 2,180,005 sh ares available for future grants under the Plan. The exercise price for each option equals the fair market value per share of the Company’s common stock on the date of grant. Substantially all stock options outstanding under the plan have terms of seven years and vest ratably over three years. No performance awards payable in stock have been awarded under the plan and no outstanding stock options under the employee plan were issued with stock appreciation rights. The following is a summary of the stock option activity under the employee plan described above:
|  | Outstanding Non-Qualified or Nonincentive Stock Option Awards |  |  | Weighted Average Exercise Price |
Outstanding at December 31, 2021 |  |  | 537,767 |  |  | $ | 70.66 |
Exercised |  |  | (47,436 | ) |  | $ | 68.09 |
Forfeited or expired |  |  | (94,166 | ) |  | $ | 74.50 |
Outstanding at December 31, 2022 |  |  | 396,165 |  |  | $ | 70.06 |
The following table summarizes information about the Company’s outstanding and exercisable stock options under the employee plan at December 31, 2022:
|  | Options Outstanding |  |  | Options Exercisable |
Range of Exercise Prices |  | Number Outstanding |  |  | Weighted Average Remaining Contractual Life in Years |  |  | Weighted Average Exercise Price |  |  | Aggregated Intrinsic Value (in thousands) |  |  | Number Exercisable |  |  | Weighted Average Exercise Price |  |  | Aggregated Intrinsic Value (in thousands) |
$51.23 |  |  | 56,207 |  |  |  | 0.1 |  |  | $ | 51.23 |  |  |  |  |  |  | 56,207 |  |  | $ | 51.23 |  |  |  |
$64.89 – $68.50 |  |  | 66,097 |  |  |  | 1.4 |  |  | $ | 67.65 |  |  |  |  |  |  | 66,097 |  |  | $ | 67.65 |  |  |  |
$73.29 – $75.50 |  |  | 267,156 |  |  |  | 3.1 |  |  | $ | 74.25 |  |  |  |  |  |  | 237,050 |  |  | $ | 74.37 |  |  |  |
$84.90 |  |  | 6,705 |  |  |  | 3.3 |  |  | $ | 84.90 |  |  |  |  |  |  | 6,705 |  |  | $ | 84.90 |  |  |  |
$51.23 – $84.90 |  |  | 396,165 |  |  |  | 2.4 |  |  | $ | 70.06 |  |  | $ | 737 |  |  |  | 366,059 |  |  | $ | 69.80 |  |  | $ | 737 |
The following is a summary of the restricted stock award activity under the employee plan described above:
|  | Unvested Restricted Stock Award Shares |  |  | Weighted Average Grant Date Fair Value Per Share |
Nonvested balance at December 31, 2021 |  |  | 18,424 |  |  | $ | 68.72 |
Vested |  |  | (17,769 | ) |  | $ | 68.75 |
Forfeited |  |  | (655 | ) |  | $ | 67.70 |
Nonvested balance at December 31, 2022 |  |  | — |  |  | $ | — |
No restricted stock awards were granted under the employee plan during 2022, 2021, and 2020. The following is a summary of RSU activity under the employee plan described above:
|  | Unvested RSUs |  |  | Weighted Average Grant Date Fair Value Per Unit |
Nonvested balance at December 31, 2021 |  |  | 590,979 |  |  | $ | 61.07 |
Granted |  |  | 208,766 |  |  | $ | 66.13 |
Vested |  |  | (149,565 | ) |  | $ | 64.43 |
Forfeited |  |  | (91,361 | ) |  | $ | 60.69 |
Nonvested balance at December 31, 2022 |  |  | 558,819 |  |  | $ | 62.13 |
The weighted average grant date fair value of RSUs granted for the years ended December 31, 2022, 2021, and 2020 was $66.13, $51.36, and $73.04, respectively. During February 2023, the Company gra nted 180,425 RSUs to selected officers and other key employees under its employee stock award plan, which vest ratably over five yea rs. The Company has a stock award plan for nonemployee directors of the Company which provides for the issuance of stock options and restricted stock. The director plan provides for automatic grants of restricted stock to nonemployee directors after each annual meeting of stockholders. In addition, the director plan allows for the issuance of stock options or restricted stock in lieu of cash for all or part of the annual director fee at the option of the director. The exercise prices for all options granted under the plan are equal to the fair market value per share of the Company’s common stock on the date of grant. The terms of the options are ten years. The restricted stock issued after each annual meeting of stockholders vests six months after the date of grant. Options granted and restricted stock issued in lieu of cash director fees vest in equal quarterly increments during the year to which they relate. At December 31, 2022, 374,751 shares were available for future grants under the director plan. The director stock award plan is intended as an incentive to attract and retain qualified independent directors. The following is a summary of the stock option activity under the director plan described above:
|  | Outstanding Non-Qualified or Nonincentive Stock Option Awards |  |  | Weighted Average Exercise Price |
Outstanding at December 31, 2021 |  |  | 88,980 |  |  | $ | 80.82 |
Exercised |  |  | (20,500 | ) |  | $ | 62.19 |
Expired |  |  | (12,000 | ) |  | $ | 87.35 |
Outstanding at December 31, 2022 |  |  | 56,480 |  |  | $ | 86.19 |
The following table summarizes information about the Company’s outstanding and exercisable stock options under the director plan at December 31, 2022:
|  | Options Outstanding |  |  | Options Exercisable |
Range of Exercise Prices |  | Number Outstanding |  |  | Weighted Average Remaining Contractual Life in Years |  |  | Weighted Average Exercise Price |  |  | Aggregate Intrinsic Value |  |  | Number Exercisable |  |  | Weighted Average Exercise Price |  |  | Aggregate Intrinsic Value |
$70.65 – $85.30 |  |  | 32,480 |  |  |  | 1.6 |  |  | $ | 76.34 |  |  |  |  |  |  | 32,480 |  |  | $ | 76.34 |  |  |  |
$99.52 |  |  | 24,000 |  |  |  | 1.1 |  |  | $ | 99.52 |  |  |  |  |  |  | 24,000 |  |  | $ | 99.52 |  |  |  |
$70.65 – $99.52 |  |  | 56,480 |  |  |  | 1.4 |  |  | $ | 86.19 |  |  | $ | — |  |  |  | 56,480 |  |  | $ | 86.19 |  |  | $ | — |
The following is a summary of the restricted stock award activity under the director plan described above:
|  | Unvested Restricted Stock Award Shares |  |  | Weighted Average Grant Date Fair Value Per Share |
Nonvested balance at December 31, 2021 |  |  | 3,337 |  |  | $ | 58.70 |
Granted |  |  | 28,696 |  |  | $ | 64.61 |
Vested |  |  | (30,335 | ) |  | $ | 63.92 |
Nonvested balance at December 31, 2022 |  |  | 1,698 |  |  | $ | 65.36 |
The weighted average grant date fair value of restricted stock awards granted under the director plan for the years ended December 31, 2022, 2021, and 2020 were $64.61, $65.13, and $49.84, respectively. The total intrinsic value of all stock options exercised under all of the Company’s plans wa s $0.4 million, $0.1 million, and $0.7 million for the years ended December 31, 2022, 2021, and 2020, respectively. The total fair value of all the restricted stock vestings under all of the Company’s plans was $3.2 million, $5.3 million, and $5.6 million for the years ended December 31, 2022, 2021, and 2020, respectively. The actual tax benefit realized for tax deductions from restricted stock vestings was $0.8 million, $1.5 million, and $1.6 million for the years ended December 31, 2022, 2021, and 2020, respectively. The total fair value of all the RSU vestings under the Company’s employee plan was $9.5 million, $4.4 million and $5.2 million for the years ended December 31, 2022, 2021, and 2020 respectively. The actual tax benefit realized for tax deductions from RSU vestings was $2.4 million, $1.2 million and $1.5 million for the years ended December 31, 2022, 2021, and 2020, respectively. As of December 31, 2022, there was $0.1 million of unrecognized compensation cost related to restricted stock and $16.2 million relate d to nonvested RSUs. The restricted stock is expected to be recognized over a weighted average period of approximately 0.4 years and RSUs over approximately 2.9 years. The weighted average per share fair value of stock options granted during the year ended December 31, 2020 was $20.19. The fair value of the stock options granted during the year ended December 31, 2020 was $2.3 million. There were no stock options granted under the employee plan during the years ended December 31, 2022 and 2021 and no stock options granted under the director plan during the years ended December 31, 2022, 2021 and 2020. The Company currently uses treasury stock shares for restricted stock grants, RSU vestings, and stock option exercises. The fair value of each stock option was determined using the Black-Scholes option pricing model. The key input variables used in valuing the stock options granted were as follows:
|  | Year Ended December 31, |
|  | 2020 |
Dividend yield |  | None |
Average risk-free interest rate |  |  | 1.3 | %
Stock price volatility |  |  | 28 | %
Estimated option term |  | 5.3 years |

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration